Ma L, Calvo F
Laboratoire de Pharmacologie Expérimentale et Clinique, Hôpital Saint Louis, Paris, France.
Fundam Clin Pharmacol. 1996;10(2):97-115. doi: 10.1111/j.1472-8206.1996.tb00153.x.
Antisense oligonucleotides designed to complement a region of a particular messenger RNA may inhibit gene expression potentially through sequence-specific hybridization. Their inhibiting effect has been shown in a variety of in vitro and in vivo models in oncology, whereas much rarer clinical trials have been carried out. Rigorous demonstration of in vitro and in vivo specific effects upon their targets is mandatory before their use as drugs in cancer therapy.
设计用于与特定信使核糖核酸区域互补的反义寡核苷酸可能通过序列特异性杂交潜在地抑制基因表达。它们的抑制作用已在肿瘤学的多种体外和体内模型中得到证实，然而进行的临床试验却少得多。在将其用作癌症治疗药物之前，必须严格证明其在体外和体内对靶点的特异性作用。
